CBAY News and Press, CymaBay Therapeutics Inc. From 08/03/20

NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...

Gainers:  Marathon Patent (NASDAQ: MARA ) +107% . More news on: Marathon Patent Group, Inc., Datasea Inc., ADT Inc., Stocks on the move, , Read more ...

Highway Holdings (NASDAQ: HIHO ) +102% . More news on: Highway Holdings Limited, ADT Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...

CymaBay Therapeutics (NASDAQ: CBAY ) announces positive results from a Phase 3 clinical trial, ENHANCE, evaluating lead drug seladelpar in patients with primary biliary cholangitis , a chronic disease in which the liver's bile ducts are slowly destroyed. More news on: CymaBay Therapeu...

The study demonstrated seladelpar to be efficacious, safe and well-tolerated 78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months (p<0.0001) 27.3% of patients on seladelpar 10 mg versus zero on placebo normalize...

Premarket  - Albertsons (NYSE: ACI ) will issue its first earnings report since the IPO. The stock attracted a wave of bullish ratings last month and is likely to have seen a positive effect on sales from the pandemic. The last grocery store operator to go public before Albertsons w...

Gainers:  Milestone Pharmaceuticals (NASDAQ: MIST ) +105% . More news on: Milestone Pharmaceuticals Inc., RigNet, Inc., Brightcove Inc., Stocks on the move, , Read more ...

CymaBay Therapeutics (NASDAQ: CBAY )   jumps 22%  premarket on the heels of its  announcement that the FDA has removed clinical holds on seladelpar for all three IND Applications in Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and Primary Sclerosing...

Liquid Media (NASDAQ: YVR ) +63% . More news on: Liquid Media Group Ltd., Milestone Pharmaceuticals Inc., CymaBay Therapeutics, Inc., Stocks on the move, , Read more ...

Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC  Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...